The clinical pharmacokinetics of darifenacin (Q34566180)

3 August 2017

1 reference

title

The clinical pharmacokinetics of darifenacin (English)

1 reference

3 August 2017

1 reference

Andrej Skerjanec

1

1 reference

3 August 2017

publication date

1 January 2006

1 reference

Clinical Pharmacokinetics

3 August 2017

published in

1 reference

3 August 2017

volume

45

1 reference

3 August 2017

issue

4

1 reference

3 August 2017

page(s)

325-350

1 reference

Absorption of ipsapirone along the human gastrointestinal tract

3 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200645040-00001

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00003088-200645040-00001

Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine

21 January 2018

1 reference

12 December 2020

Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder

1 reference

12 December 2020

Assessment of cognitive function of the elderly population: effects of darifenacin

1 reference

12 December 2020

Muscarinic antagonists in development for disorders of smooth muscle function

1 reference

12 December 2020

Drug treatment of overactive bladder: efficacy, cost and quality-of-life considerations.

1 reference

12 December 2020

Darifenacin in the treatment of overactive bladder

1 reference

12 December 2020

International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

1 reference

12 December 2020

The overactive bladder: pharmacologic basis of drug treatment

1 reference

12 December 2020

A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder

1 reference

12 December 2020

Functional role of P-glycoprotein in limiting intestinal absorption of drugs: contribution of passive permeability to P-glycoprotein mediated efflux transport

1 reference

12 December 2020

The standardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society.

1 reference

12 December 2020

Treatment of overactive bladder in the older patient: pooled analysis of three phase III studies of darifenacin, an M3 selective receptor antagonist

1 reference

12 December 2020

Assessment of the relative in vivo potency of the hydroxylated metabolite of darifenacin in its ability to decrease salivary flow using pooled population pharmacokinetic-pharmacodynamic data

1 reference

12 December 2020

Molecular basis of ethnic differences in drug disposition and response

1 reference

12 December 2020

Population pharmacokinetic modelling of darifenacin and its hydroxylated metabolite using pooled data, incorporating saturable first‐pass metabolism, CYP2D6 genotype and formulation‐dependent bioavailability

1 reference

12 December 2020

Anticholinergic drugs used in Parkinson's disease: An overlooked class of drugs from a pharmacokinetic perspective

1 reference

12 December 2020

Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment

1 reference

12 December 2020

QT and QTc interval with standard and supratherapeutic doses of darifenacin, a muscarinic M3 selective receptor antagonist for the treatment of overactive bladder

1 reference

12 December 2020

Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients

1 reference

12 December 2020

The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro

1 reference

12 December 2020

Discovery & development of selective M3 antagonists for clinical use.

1 reference

12 December 2020

Antimuscarinic drugs for overactive bladder and their potential effects on cognitive function in older patients

1 reference

12 December 2020

Polymorphic 2-hydroxylation of desipramine. A population and family study

1 reference

12 December 2020

Paroxetine shifts imipramine metabolism

1 reference

12 December 2020

Rapid, solid phase extraction technique for the high-throughput assay of darifenacin in human plasma

1 reference

12 December 2020

Pharmacokinetics and metabolism of darifenacin in the mouse, rat, dog and man.

1 reference

12 December 2020

Dose response with darifenacin, a novel once-daily M3 selective receptor antagonist for the treatment of overactive bladder: results of a fixed dose study

1 reference

12 December 2020

10.2165/00003088-200645040-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

3 August 2017

1026672495

0 references

1 reference